REVIEW OF THERAPEUTICS
Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists
Nimish Patel,
Jeannette Bouchard,
Meredith B. Oliver,
Melissa E. Badowski,
Joseph J. Carreno,
On Behalf of the Society of Infectious Diseases Pharmacists,
Nimish Patel
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA
Search for more papers by this authorJeannette Bouchard
WakeMed Health & Hospitals, Raleigh, North Carolina, USA
Search for more papers by this authorMeredith B. Oliver
M Health Fairview University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA
Search for more papers by this authorMelissa E. Badowski
College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA
Search for more papers by this authorCorresponding Author
Joseph J. Carreno
Albany College of Pharmacy and Health Sciences, Albany, New York, USA
Correspondence
Joseph J. Carreno, 106 New Scotland Ave, Albany, NY 12208, USA.
Email: [email protected]
Search for more papers by this authorthe Society of Infectious Diseases Pharmacists
Search for more papers by this authorNimish Patel,
Jeannette Bouchard,
Meredith B. Oliver,
Melissa E. Badowski,
Joseph J. Carreno,
On Behalf of the Society of Infectious Diseases Pharmacists,
Nimish Patel
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA
Search for more papers by this authorJeannette Bouchard
WakeMed Health & Hospitals, Raleigh, North Carolina, USA
Search for more papers by this authorMeredith B. Oliver
M Health Fairview University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA
Search for more papers by this authorMelissa E. Badowski
College of Pharmacy, University of Illinois Chicago, Chicago, Illinois, USA
Search for more papers by this authorCorresponding Author
Joseph J. Carreno
Albany College of Pharmacy and Health Sciences, Albany, New York, USA
Correspondence
Joseph J. Carreno, 106 New Scotland Ave, Albany, NY 12208, USA.
Email: [email protected]
Search for more papers by this authorthe Society of Infectious Diseases Pharmacists
Search for more papers by this authorAbstract
As of August 2021, there were three COVID-19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID-19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA-1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real-world effectiveness investigations post-authorization. These studies indicate that immunity is obtained within 2 weeks post-vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS-CoV-2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID-19 vaccine programs.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
- 1 United States Food and Drug Administration. Emergency use authorization for vaccines explained | FDA [online]. Accessed April 15, 2021. https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained.
- 2 United States Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19 [online]. Accessed May 27, 2021. https://www.fda.gov/media/139638/download.
- 3 Kaiser Family Foundation. KFF COVID-19 vaccine monitor [online]. Accessed August 18, 2021. https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-monitor-dashboard/.
- 4Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383: 2603-2615.
- 5Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384: 403-416.
- 6Sadoff J, Gray G, Vandebosch AN, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021; 384(23): 2187-2201.
- 7Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines. Clin Infect Dis. 2021. [Online ahead of print].
- 8Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384: 1412-1423.
- 9Daniel W, Nivet M, Warner J, Podolsky DK. Early evidence of the effect of SARS-CoV-2 vaccine at one medical center. N Engl J Med. 2021; 384: 1962-1963.
- 10Keehner J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021; 384: 1774-1775.
- 11Tande AJ, Pollock BD, Shah ND, et al. Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening. Clin Infect Dis. 2021. [Online ahead of print].
- 12Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – eight U.S. locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 495-500.
- 13Tang LI, Hijano DR, Gaur AH, et al. Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce. JAMA. 2021; 325: 2500.
- 14Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021; 4:e2035057.
- 15Patel MM, Jackson ML, Ferdinands J. Postlicensure evaluation of COVID-19 vaccines. JAMA. 2020; 324: 1939-1940.
- 16Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021; 325: 2201.
- 17Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring – United States, December 14, 2020–January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 283-288.
- 18 CDC Covid-Response Team Food Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine – United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021; 70: 46-51.
- 19 Centers for Disease Control and Prevention Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States [online]. Accessed August 13, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.
- 20Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021; 148 (3): e2021052478.
- 21 Centers for Disease Control and Prevention ACIP presentation slides: June 23–25, 2021 meeting [online]. Accessed August 14, 2021. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/03-COVID-Shimabukuro-508.pdf.
- 22 Pfizer Inc Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study [online]. Accessed April 15, 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious.
- 23Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021; 384: 2259-2261.
- 24McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021; 590: 630-634.
- 25Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021. [Online ahead of print].
- 26Valdivia A, Torres I, Latorre V, et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays. Eur J Clin Microbiol Infect Dis. 2021; 40: 485-494.
- 27 United States Food and Drug Administration. FDA in brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination [online]. Accessed May 21, 2021. https://www.fda.gov/news-events/press-announcements/fda-brief-fda-advises-against-use-sars-cov-2-antibody-test-results-evaluate-immunity-or-protection.
- 28Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021; 2: e240-e249.
- 29 National Health Service England. C0994-system-letter-COVID-19-vaccination-deployment-planning-30-December-2020.pdf [online]. Accessed April 15, 2021. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/12/C0994-System-letter-COVID-19-vaccination-deployment-planning-30-December-2020.pdf.
- 30Moghadas SM, Vilches TN, Zhang K, et al. Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLoS Biol. 2021; 19:e3001211.
- 31Romero-Brufau S, Chopra A, Ryu AJ, et al. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study. BMJ. 2021; 373: n1087.
- 32Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021; 325: 1467-1469.
- 33Bradley T, Grundberg E, Selvarangan R, et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021; 384: 1959-1961.
- 34 Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions [online]. Accessed May 26, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Concern.
- 35Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021; 371: 1152-1153.
- 36Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593: 130-135.
- 37Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021; 596: 273-275.
- 38Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021; 397: 2331-2333.
- 39Choi A, Koch M, Wu K, et al. Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants. bioRxiv. 2021:2021.2006.2028.449914.
- 40 Janssen Scientific Affairs LLC. Janssen COVID-19 vaccine (Ad26.COV2.S) [online]. Accessed August 12, 2021. https://www.janssenmd.com/janssen-covid19-vaccine/clinical-data/efficacy/variants/use-of-the-janssen-covid19-vaccine-in-variants-of-sarscov2.
- 41Abu-Raddad LJ, Chemaitelly H, Butt AA, Vaccination NSGfC. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021; 385: 187-189.
- 42Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397: 1725-1735.
- 43Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397: 2461-2462.
- 44Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021; 385: 585-594.
- 45Nasreen S, Chung H, He S, et al. Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada. medRxiv 2021:2021.2006.2028.21259420.
- 46Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020; 370: m3320.
- 47Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021; 175: 817-826.
- 48Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021; 175: 594.
- 49Joseph NT, Dude CM, Verkerke HP, et al. Maternal antibody response, neutralizing potency, and placental antibody transfer after severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection. Obstet Gynecol. 2021; 138(2): 189–197.
- 50Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021; 255(3): e11–303.e17.
- 51Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021; 384(24): 2273–2282.
- 52Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021; 325(23): 2370–2380.
- 53 United States Census Bureau. Age and sex composition in the United States: 2019 [online]. Accessed May 26, 2021. https://www.census.gov/data/tables/2019/demo/age-and-sex/2019-age-sex-composition.html.
- 54Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020; 383: 334-346.
- 55Goyal MK, Simpson JN, Boyle MD, et al. Racial and/or ethnic and socioeconomic disparities of SARS-CoV-2 infection among children. Pediatrics. 2020; 146:e2020009951.
- 56Santoli JM, Lindley MC, DeSilva MB, et al. Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 591-593.
- 57Kim L, Whitaker M, O'Halloran A, et al. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 – COVID-NET, 14 states, March 1–July 25, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 1081-1088.
- 58 American Academy of Pediatrics. Children and COVID-19: state-level data report [online]. Accessed May 26, 2021. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.
- 59 United States Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic [online]. Accessed May 15, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use.
- 60 Committee on Infectious Diseases. COVID-19 vaccines in children and adolescents. Pediatrics. 2021; 148(2): e2021052336.
